John Shen, MD

GU Medical Oncologist & #GeriOnc

[John Shen, MD @johnshenmd]

@DrRanaMcKay @CaPsurvivorship @AlanBryce9 @EAntonarakis @RenuEapen @zklaassen_md 🤣 amazing

[John Shen, MD @johnshenmd]

@Dan_ChangMD @ACKoongMDPhD The two of you could sub in for Harbaugh !

[Targeted Oncology @TargetedOnc]

In the phase 1/2 APEX-01 study, ARX517 led to preliminary efficacy and displayed a strong safety profile when used as a treatment for patients with #mCRPC. #ESMO23 | @johnshenmd @UCLAJCCC

https://t.co/CcQ75cx4fa

[OncLive.com @OncLive]

ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC @johnshenmd @UCLAJCCC @myESMO #ESMO23 #ESMO2023 #pcsm #oncology https://t.co/6oaORseJVq

[Zach Klaassen @zklaassen_md]

APEX-01: First-in-human Ph 1/2 study of ARX517, an anti-PSMA ADC, in mCRPC #ESMO23 @urotoday

🚩n=65, median 4 prior LoT
🚩Gr 1/2 TRAEs: dry mouth (28%), fatigue (20%), diarrhea (15%)
🚩52%: ≥50% PSA ⬇️ at therapeutic doses ≥ 2.0 mg/kg
🚩⬇️≥ 50% in ctDNA: 81% cohorts 6-8
🚩Target lesion reduction: 56% in cohorts 4-8

[UroToday.com @urotoday]

Phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor degrader, in #mCRPC: radiographic PFS in patients with AR ligand-binding domain mutations. Presentation by @DanielPetrylak @YaleCancer. #ESMO23 coverage by @zklaassen_md @GACancerCenter > https://t.co/xHeQdRSMr3

[John Shen, MD @johnshenmd]

Rapid prostate abstracts this AM incl: KN-641, KN-991, MAGNITUDE, & ProBio - interesting to see novel trial design. Impt msg from @mishabeltran - pt selection & testing remain critical to help determine who benefits #ESMO23

[John Shen, MD @johnshenmd]

@PercyLeeMD @cityofhopeoc @AWalkerHealth @DrEdKim @TeWilliamsMD @ASchwerMD @cityofhope So Radiation DOES work on the weekend…

[John Shen, MD @johnshenmd]

*NOT* a DAD joke: dual ADC study of SG+EV in pre-treated mUC. Impressive RR, will need to balance tox & explore additional combos. #ESMO23

[John Shen, MD @johnshenmd]

Updates from RADICALS-RT at #ESMO23 🇪🇸. Why do I have a feeling this may come up again at tumor board @AmarUKishan @RobertReiterMD @Adam_Weiner535 @PKanaburMD

[John Shen, MD @johnshenmd]

Excellent session on advanced RCC by @DrChoueiri @crisuarez08 @tompowles1 how far it’s come & what the future may hold #ESMO23

[John Shen, MD @johnshenmd]

So great to see #GeriOnc highlighted early in the #ESMO23 program @ravikanesvaran @SIOGorg

[John Shen, MD @johnshenmd]

Opening session at #ESMO23 looking forward to seeing all the practice-changing data @Silke_Gillessen

[John Shen, MD @johnshenmd]

BIG NEWS in Advanced Bladder Cancer

[Tom Powles @tompowles1]

EV302- enfortumab vedotin and Pembrolizumab met its dual primary endpoints of OS and PFS with ‘clinically meaningful’ improvement versus chemotherapy in patients with previously untreated la/mUC. https://t.co/NRb4DhQR2C

[John Shen, MD @johnshenmd]

Great sessions, shared stories, life experiences & lessons learned 👏 kudos to @PCFnews @charlesryanmd @WilliamOhMD

[Neeraj Agarwal, MD, FASCO @neerajaiims]

@PCFnews Thought Leaders of the Future Program👉 one of the most enlightening talks was by @morr316 on how to improve the currently high-burden, clinical trial system👉Pragmatic and decentralized trials, & “project pragmatica” 👇@PCF_Science @urotoday @OncBrothers @OncoAlert

[. @UCLAJCCC]

We are proud to announce that UCLA Health Jonsson Comprehensive Cancer Center has been recognized as #1 in California and #4 in the nation for cancer care by @usnews. More here: https://t.co/2OgE2Te9gJ

[John Shen, MD @johnshenmd]

Great keynote session by @AmerCancerCEO Dr. Knudsen highlighting the importance of research, patient support, & advocacy in cancer care. @UCLAJCCC Retreat. Also excellent prostate cancer session moderated by @RobertReiterMD, including @AmarUKishan, @CzerninJohannes, & more

[Amar Kishan @AmarUKishan]

Nice work out in @IJROBP led by @UCLAJCCC resident @claysmithmd https://t.co/01q4kQxSpZ. Detailed patterns of failure analysis in 128 patients with PSMA done for radiorecurrent disease, revealing intraprostatic-only failures in ~1/3.

[John Shen, MD @johnshenmd]

Thanks for mentoring our future aging researchers! Few more days for interested medical students to apply for this summer: https://t.co/1Zd0kfSqBb @UCLAGeriFellows @DOM_UCLA @errorbars

[Eric H Yang, MD @datsunian]

Some great #MedEd work from @katieptr @MeganKamath and visiting student #yordanoselala @BoulierKristin studying statin prescribing trends in Heme malignancies during his MSTAR fellowship

#cardioonc

12/

[Eric H Yang, MD @datsunian]

.Proud to show a product of @DOM_UCLA @uclaimchiefs MS Research Fellowship led by @dgsomucla #NikithaKosaraju & @UCIrvineHealth @Perrycardial in @WileyHealth #ClinicalCardiology

Great collab of #cardioonc @UCLA_IC @UCLAJCCC & #TAVR teams

https://t.co/4whXLJK6Zd
@IntMedAbel 1/